EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 10th, 2007 • Cytrx Corp • Biological products, (no disgnostic substances) • Massachusetts
This Agreement, effective as of January 10, 2007 (the “Effective Date”), is between the University of Massachusetts (“University”), a public institution of higher education of the Commonwealth of Massachusetts as represented by its Worcester campus, and RXi Pharmaceuticals Corporation (“Company”), a Delaware corporation.
CONTRIBUTION AGREEMENT by and between CYTRX CORPORATION and RXI PHARMACEUTICALS CORPORATION January 8, 2007Contribution Agreement • May 10th, 2007 • Cytrx Corp • Biological products, (no disgnostic substances) • New York
THIS CONTRIBUTION AGREEMENT is dated as of January 8, 2007 and is made by and between CytRx Corporation, a Delaware corporation (“CytRx”), and RXi Pharmaceuticals Corporation, a Delaware corporation (“RXi”). CytRx and RXi are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
NON-EXCLUSIVE LICENSE AGREEMENTNon-Exclusive License Agreement • May 10th, 2007 • Cytrx Corp • Biological products, (no disgnostic substances) • Massachusetts
This Agreement, effective as of January 10, 2007 (the “Effective Date”), is between the University of Massachusetts (“University”), a public institution of higher education of the Commonwealth of Massachusetts as represented by its Worcester campus, and, RXi Pharmaceuticals Corporation (“Company”), a Delaware corporation.
INVENTION DISCLOSURE AGREEMENTInvention Disclosure Agreement • May 10th, 2007 • Cytrx Corp • Biological products, (no disgnostic substances) • Massachusetts
This Agreement, effective as of the Effective Date, as defined below, is between the University of Massachusetts, as represented solely by the Medical School at its Worcester campus (the “Medical School”), a public institution of higher education of the Commonwealth of Massachusetts, and RXi Pharmaceuticals Corporation (“Company”), a Delaware corporation.
Office of Technology Management University of Massachusetts Medical School 333 South Street, Suite 400 Shrewsbury, MA 01545 Attention: Executive DirectorLicense Agreement • May 10th, 2007 • Cytrx Corp • Biological products, (no disgnostic substances)
Re: License Agreements between the University of Massachusetts (the “University”) and RXi Pharmaceuticals, Inc. (the “Company”) dated as of January 10, 2007 (the “License Agreements”)
Master Agreement for Clinical Trials Management ServicesMaster Agreement for Clinical Trials Management Services • May 10th, 2007 • Cytrx Corp • Biological products, (no disgnostic substances) • Delaware
This Master Agreement for Clinical Trials Management Services (the “Agreement”) is made and entered into this 30th day of November, 2006, by and between CytRx Corporation, a corporation of California with offices at 11726 San Vicente Blvd., Los Angeles, CA 90049 (hereinafter referred to as “Sponsor”) and Pharmaceutical Research Associates, Inc., a corporation of the Commonwealth of Virginia, together with its Affiliates with offices at 12120 Sunset Hills Road, Suite 600, Reston, Virginia 20190 (hereinafter referred to as “PRA”), both hereinafter referred as “Parties”
January 8, 2007 Tod Woolf President RXi Pharmaceuticals Corporation One Innovation Drive Worcester, MA 01605 Re: Reimbursement of fees and expenses Dear Tod:Reimbursement Agreement • May 10th, 2007 • Cytrx Corp • Biological products, (no disgnostic substances) • California
This letter agreement (this “Agreement”) is between CytRx Corporation (“CytRx”) and RXi Pharmaceuticals Corporation (“RXi”), each a Delaware corporation, with respect to certain fees and expenses incurred by CytRx in connection with the anticipated (i) contribution by CytRx to RXi of certain RNAi-related assets, and (ii) either (a) the sale of RXi securities to one or more accredited investors in a single financing transaction or series of related financing transactions (a “RXi Offering”) or (b) the sale by CytRx of its securities and an subsequent investment by CytRx in RXi (a “CytRx Offering”, and, together with a RXi Offering, an “Offering”).
EMPLOYMENT AGREEMENTEmployment Agreement • May 10th, 2007 • Cytrx Corp • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”) is made and entered into as of February 22, 2007 (“Effective Date”) by and between RXi Pharmaceuticals Corporation (“Employer”), a Delaware corporation and a majority owned subsidiary of CytRx Corporation, a Delaware corporation (“CytRx”), and Tod Woolf, an individual and resident of the Commonwealth of Massachusetts (“Employee”).
CONTRIBUTION AGREEMENT between CYTRX CORPORATION and RXi PHARMACEUTICALS CORPORATION April 30, 2007Contribution Agreement • May 10th, 2007 • Cytrx Corp • Biological products, (no disgnostic substances) • Delaware
THIS CONTRIBUTION AGREEMENT (this “Agreement”) is dated as of April 30, 2007 and is made by and between CytRx Corporation, a Delaware corporation (“CytRx”), and RXi Pharmaceuticals Corporation, a Delaware corporation and majority-owned subsidiary of CytRx (“RXi”). CytRx and RXi are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
